103 primary care centres across the UK took part in the PERSIST study between January 2005 and January 2006, with 1,076 women each agreeing to participate for a six-month period.
542 were prescribed a single 70mg dose of alendronate once a week and the remainder received a single monthly 150mg dose of ibandronate and were enrolled in a free patient support programme designed to complement the drug.
The monthly ibandronate group received a welcome pack providing basic information about osteoporosis and a monthly reminder call from a trained nurse one to three days before the dose was due.
The nurses also used the opportunity to confirm dosing instructions, provide further information about osteoporosis and stress the importance of adhering to the treatment regime.
835 women completed the study, leaving 440 in the monthly ibandronate group and 395 in the weekly alendronate group.
Of these, just under 57 per cent of patients receiving monthly ibandronate tablets, together with patient support, were taking the medication after six months. The persistence rate for patients on weekly alendronate tablets was 39 per cent.
“Getting patients to continue taking prescribed medication is a major problem for healthcare professionals” says lead author Dr Alun Cooper, a family doctor from the Bridge Medical Centre in Crawley, UK.
“The World Health Organization estimates that only 50 per cent of patients with chronic diseases in developing countries stick to treatment regimes. And the American Heart Association has identified failing to take medication correctly as the number one problem in treating ill health today.
According to the International Osteoporosis Foundation one in three women over 50 suffer from osteoporosis worldwide.
“Sufferers find that their bones become increasingly brittle and this increases the risk of serious factures, especially if they don’t take their medication on a regular basis” says Dr Cooper. “It’s estimated that one in two women over 50 will experience a fracture at some time because of fragile bones, so any treatment regime that improves compliance is to be welcomed.”
The women who took part in the study had an average age of 68 and more than a third had a family history of osteoporosis.
45 per cent had already suffered a fracture, with just under a third reporting one incident and a further ten per cent reporting two. Four per cent had experienced three to five factures.
“Our study clearly shows that women who were prescribed monthly doses of ibandronate, and enrolled on a patient support programme, were much more likely to continue taking their medication than those on weekly doses of alendronate” concludes Dr Cooper.
“Evidence suggests that adhering to regular treatment for osteoporosis improves bone mass density and reduces fracture rates. This, in turn, reduces the social and economic burden of this very common and debilitating chronic condition.”
Over 100 family doctors from more than 30 counties across the UK took part in the PERIST research, which was supported by Roche Products Limited.
Annette Whibley | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
21.03.2018 | Physics and Astronomy
21.03.2018 | Materials Sciences
21.03.2018 | Life Sciences